Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06263244 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Specifying the Anti-inflammatory Effects of Ziltivekimab

Study acronym: SPIDER
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 6, 2026 (before its estimated September 4, 2026 completion). Its status may not reflect the trial's current state.
Trial flagged as At Risk
Primary completion moved at least 2 months later Jul 1, 2026 → Sep 4, 2026
See other at-risk trials from Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Record History

  1. Enrollment closed, study ongoing Primary completion pushed from Jul 1, 2026 to Sep 4, 2026 · Completion date: Oct 1, 2026 to Oct 30, 2026 · Site details revisedv4 Show 3 more changesShow less
    • Primary completion pushed from Jul 1, 2026 to Sep 4, 2026
    • Completion date: Oct 1, 2026 to Oct 30, 2026
    • Site details revised
  2. Trial status: Not Yet Recruiting to Recruiting Primary completion date: Mar 1, 2025 to Jul 1, 2026 · Study sites: 0 to 1 · Completion date: Apr 1, 2025 to Oct 1, 2026 · 1 morev3 Show 4 more changesShow less
    • Primary completion date: Mar 1, 2025 to Jul 1, 2026
    • Study sites: 0 to 1
    • Completion date: Apr 1, 2025 to Oct 1, 2026
    • Start date changed from estimate of Apr 1, 2024 to May 3, 2024
  3. Secondary endpoints: 6 to 8v2 See this version in full on ClinicalTrials.gov ↗
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this randomized, double blind, placebo controlled trial is to study whether ziltivekimab therapy reduces arterial wall inflammation as assessed by imaging, and reduces the systemic inflammatory tone as assessed by circulating monocytes, inflammatory biomarkers and proteomics.
Trial Details
NCT Number NCT06263244
Lead Sponsor Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Conditions Atherosclerosis, Inflammation
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov